2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients

      European Heart Journal Supplements
      Oxford University Press (OUP)

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Most cited references18

          • Record: found
          • Abstract: found
          • Article: not found

          Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study.

          Weight loss in chronic heart failure is linked to impaired survival. We aimed to assess the frequency of weight loss in patients with this disease, whether the degree of weight loss predicts mortality, and whether weight loss can be prevented by angiotensin-converting-enzyme (ACE) inhibitors. We investigated weight changes in 1929 patients from the SOLVD trial who had chronic heart failure, were free of oedema at baseline, and survived for at least 4 months after trial entry. Meanfollow-up was 35 months (SD 13). We analysed the effect of weight loss at cutpoints of 5%, 7.5%, 10%, 15% (a priori), and 6% (post hoc) to identify which one best predicted outcome. To validate results, we analysed data for 619 patients in the V-HeFT II trial. 817 (42%) patients in the SOLVD trial had weight loss from baseline of 5% or more. At 8 months follow-up, all cutpoints for weight loss were significantly associated with impaired survival after adjustment for age, sex, New York Heart Association class, left ventricular ejection fraction, and treatment allocation. Weight loss of 6% or more at any time during follow-up was the strongest predictor of impaired survival (adjusted hazard ratio 2.10, 95% CI 1.77-2.49; p<0.0001). Patients on the ACE inhibitor enalapril had a lower hazard of 6% or more weight loss than did those not taking the drug (adjusted reduction 19%, p=0.0054). Results from analyses of V-HeFT II data lent support to our findings. Weight loss occurs frequently in patients with chronic heart disease, its reversal is rare, and when present, it is independently linked to impaired survival. Weight loss of more than 6% should be used to define the presence of cachexia in patients with chronic heart failure. In chronic heart failure, treatment with an ACE inhibitor reduces the risk of weight loss.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Effect of sibutramine on weight maintenance after weight loss: a randomised trial

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Weight loss attempts in adults: goals, duration, and rate of weight loss.

              Although attempted weight loss is common, little is known about the goals and durations of weight loss attempts and the rates of achieved weight loss in the general population.
                Bookmark

                Author and article information

                Journal
                European Heart Journal Supplements
                Oxford University Press (OUP)
                1554-2815
                1520-1554
                November 2005
                November 01 2005
                November 2005
                November 2005
                November 01 2005
                November 2005
                : 7
                : suppl_L
                : L44-L48
                Article
                10.1093/eurheartj/sui086
                5acc9d30-52ae-48be-bd8f-efd2a0595819
                © 2005
                History

                Comments

                Comment on this article